Inotiv, Inc. Enhances Histopathology Offering with Announcement of Agreement to Purchase HistoTox Labs, Inc.

Inotiv, Inc. Enhances Histopathology Offering

with Announcement of Agreement to Purchase HistoTox Labs, Inc.

WEST LAFAYETTE, IN, April 13, 2021 - Inotiv, Inc.

(NASDAQ:NOTV) (the "Company", "We", "Our" or "Inotiv"), a leading provider of nonclinical

and analytical contract research services, today announced that the Company has entered into an agreement to purchase substantially all

of the assets of HistoTox Labs, Inc. ("HistoTox Labs"), a full-service histopathology contract research organization ("CRO")

offering medically relevant non-clinical and clinical services to the pharmaceutical, biotech, and academic communities.

"HistoTox Labs' well-trained scientific staff, with strong

expertise in cell-typing, biodistribution, gene therapy and novel biomarker assay development, is a solid and strategic complement to

Inotiv's pathology team and our suite of services," said Robert Leasure, Jr., Inotiv's President and Chief

Executive Officer. "More than two-thirds of HistoTox's client base consists of emerging biopharma companies focused on cell

and gene therapy, dovetailing well with our growth strategy."

Mr. Leasure continued, "Over the past three years, HistoTox

Labs has grown revenue organically at a compounded annual growth rate in excess of 30%. We believe that we have identified excellent cross-selling

opportunities and expect to leverage their newly renovated facility in Boulder, CO, which we estimate has the capacity to accommodate

an increase in HistoTox Labs' revenue from 2020 levels. This acquisition positions us for further growth and enables us to better

serve our clients and help them achieve their research and development goals."

In addition to the routine histology and pathology capability at HistoTox

Labs, the immunohistochemistry and digital pathology capability is cutting edge, featuring a vast library of optimized antibodies and

topflight technology such as AT2 (Aperio) high-throughput slide scanners, a Vectra Polaris Immunofluorescent slide scanner and the

Visiopharm software solutions platform including AI capabilities for their image analysis needs.

"Since 2003, HistoTox Labs has been building an exceptional team

while fostering a culture dedicated to scientific expertise, outstanding customer service and excellence in both the quality and timeliness

of data we deliver," added Jon Bishop, Chief Executive Officer of HistoTox Labs. "I am very proud of what we have accomplished

and I am confident that partnering with Inotiv will continue to bolster the HistoTox Lab's team and create a meaningful impact on

our clients' drug development success."

Transaction Snapshot

The Company expects to retain all existing HistoTox Labs employees

after transaction close.

The transaction is subject to customary closing processes and financing.

A Current Report on Form 8-K containing further details regarding the contemplated transaction will be filed by Inotiv and made available

on the U.S. Securities and Exchange Commission's EDGAR website.

Inotiv, Inc., is a pharmaceutical development

company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading

drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients'

discovery and development objectives for improved decision-making and accelerated goal attainment. The Company's products focus

on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit inotivco.com for more information

This release may contain forward-looking statements

that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and

demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and

regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the

impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken

by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties and various

other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.